METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
申请人:Haggerty Timothy J.
公开号:US20140335050A1
公开(公告)日:2014-11-13
The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.
Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites
作者:Kyeong Lee、Jung S. Ryu、Yinglan Jin、Woncheol Kim、Navneet Kaur、Sang J. Chung、Yong-Jin Jeon、Joon-Tae Park、Ji S. Bang、Hong S. Lee、Tae Y. Kim、Jung J. Lee、Young-Soo Hong
DOI:10.1039/b713407j
日期:——
A new series of geldanamycin derivatives were synthesized using a semi-synthetic approach involving genetically engineered biosynthetic intermediates. These analogues were then evaluated for anti-proliferation activity in human cancer cell lines, SK-Br3 and SK-Ov3. Most of the synthesized compounds exhibited potent in vitro anti-proliferation activity toward both cell lines. Such compounds potently inhibited the expression of the Hsp90 client protein ErbB2.